Современные представления о возможностях вторичной профилактики «атопического марша» у детей с атопическим дерматитом

Атопический дерматит (АтД) является одним из самых распространенных воспалительных заболеваний детского возраста и первым звеном поэтапного развития аллергических заболеваний — «атопического марша». Формирование сенсибилизации на фоне неконтролируемого течения АтД ассоциировано с высоким риском развития серьезных аллергических патологий, увеличением степени тяжести течения болезни и снижением качества жизни пациентов. В связи с этим при тяжелом АтД у детей с ранним развитием заболевания необходимо добиться быстрого купирования воспалительного процесса. В статье рассмотрены современные терапевтические подходы к контролю заболевания у детей.

1. Maliyar K, Sibbald C, Pope E, Gary Sibbald R. Diagnosis and Management of Atopic Dermatitis. Adv Skin Wound Care. 2018;31(12):538–550. doi: 10.1097/01.asw.0000547414.38888.8d.

2. Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol. 1994;30(1):35–39. doi: 10.1016/s0190-9622(94)70004-4.

3. Kowalska-Oledzka E, Czarnecka M, Baran A. Epidemiology of atopic dermatitis in Europe. J Drug Assess. 2019;8(1):126–128. doi: 10.1080/21556660.2019.1619570.

4. Spergel JM. Epidemiology of atopic dermatitis and atopic march in children. Immunol Allergy Clin North Am. 2010;30:269–280. doi: 10.1016/j.iac.2010.06.003.

5. Круглова Л.С., Генслер Е.М. Атопический дерматит: новые горизонты терапии // Медицинский Алфавит. Дерматология. — 2019. — Т. 1. — № 7(382). — С. 29–32. doi: 10.33667/2078-5631-2019-1-7(382)-29-32.

6. Zheng T, Yu J, Oh MH, Zhu Z. The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma. Allergy Asthma Immunol Res. 2011;3(2):67–73. doi: 10.4168/aair.2011.3.2.67.

7. Irvine AD, Mina-Osorio P. Disease trajectories in childhood atopic dermatitis: an update and practitioner’s guide. Br J Dermatol. 2019; 181(5):895–906. doi: 10.1111/bjd.17766.

8. Aw M, Penn J, Gauvreau GM, et al. Atopic March: Collegium Internationale Allergologicum Update 2020. Int Arch Allergy Immunol. 2020;181(1):1–10. doi: 10.1159/000502958.

9. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016; 387(10023):1109–1122. doi: 10.1016/S0140-6736(15)00149-X.

10. Dharmage SC, Lowe AJ, Matheson MC, et al. Atopic dermatitis and the atopic march revisited. Allergy. 2014;69(1):17–27. doi: 10.1111/all.12268.

11. Loh W, Tang M. The Epidemiology of Food Allergy in the Global Context. Int J Environ Res Public Health. 2018;15(9):2043. doi: 10.3390/ijerph15092043.

12. Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(8537): 733–743. doi: 10.1016/S0140-6736(06)69283-0.

13. Bantz SK, Zhu Z., Zheng T, et al. The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma. J Clin Cell Immunol. 2014;5(2):202. doi: 10.4172/2155-9899.1000202.

14. Lowe AJ, Carlin JB, Bennett CM, et al. Do boys do the atopic march while girls dawdle? J Allergy Clin Immunol. 2008;121(5): 1190–1195. doi: 10.1016/j.jaci.2008.01.034.

15. Knudsen TB, Thomsen SF, Nolte H, Backer V. A populationbased clinical study of allergic and non-allergic asthma. J Asthma. 2009;46(1):91–94. doi: 10.1080/02770900802524657.

16. Leynaert B, Neukirch C, Kony S, et al. Association between asthma and rhinitis according to atopic sensitization in a populationbased study. J Allergy Clin Immunol. 2004;113(1):86–93. doi: 10.1016/j.jaci.2003.10.010.

17. Peters RL, Koplin JJ, Gurrin LC, et al. The prevalence of food allergy and other allergic diseases in early childhood in a populationbased study: HealthNuts age 4-year follow-up. J Allergy Clin Immunol. 2017;140(1):145–153.e8. doi: 10.1016/j.jaci.2017.02.019.

18. Hill DA, Spergel JM. The atopic march: Critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018;120(2): 131–137. doi: 10.1016/j.anai.2017.10.037.

19. Belgrave DCM, Granell R, Simpson A, et al. Developmental profiles of eczema, wheeze, and rhinitis: two population-based birth cohort studies. PLoS Med. 2014;11(10):e1001748. doi: 10.1371/journal.pmed.1001748.

20. Davidson WF, Leung DYM, Beck LA, et al. Report from the National Institute of Allergy and Infectious Diseases workshop on “Atopic dermatitis and the atopic march: Mechanisms and interventions”. J Allergy Clin Immunol. 2019;143(3):894–913. doi: 10.1016/j.jaci.2019.01.003.

21. Wisniewski JA, Agrawal R, Minnicozzi S, et al. Sensitization to food and inhalant allergens in relation to age and wheeze among children with atopic dermatitis. Clin Exp Allergy. 2013;43(10): 1160–1170. doi: 10.1111/cea.12169.

22. Romeo MJ, Agrawal R, Pomes A, Woodfolk J. A molecular perspective on TH2-promoting cytokine receptors in patients with allergic disease. J Allergy Clin Immunol. 2014;133(4):952–960. doi: 10.1016/j.jaci.2013.08.006.

23. Kelleher MM, Dunn-Galvin A, Gray C, et al. Skin barrier impairment at birth predicts food allergy at 2 years of age. J Allergy Clin Immunol. 2016;137(4):1111–1116.e8. doi: 10.1016/j.jaci.2015.12.1312.

24. Flohr C, England K, Radulovic S, et al. Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age. Br J Dermatol. 2010;163(6):1333–1336. doi: 10.1111/j.1365-2133.2010.10068.x.

25. Brough HA, Simpson A, Makinson K, et al. Peanut allergy: effect of environmental peanut exposure in children with filaggrin loss-offunction mutations. J Allergy Clin Immunol. 2014;134(4):867–875. e1. doi: 10.1016/j.jaci.2014.08.011.

26. McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol. 2013;131(2):280–291. doi: 10.1016/j.jaci.2012.12.668.

27. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010; 11(5):373–384. doi: 10.1038/ni.1863.

28. Hradetzky S, Werfel T, Rosner LM. Autoallergy in atopic dermatitis. Allergo J Int. 2015;24(1):16–22. doi: 10.1007/s40629-015-0037-5.

29. Hammad H, Lambrecht BN. Barrier epithelial cells and the control of type 2 immunity. Immunity. 2015;43(1):29–40. doi: 10.1016/j.immuni.2015.07.007.

30. Han H, Roan F, Ziegler SF, et al. The atopic march: current insights into skin barrier dysfunction and epithelial cell-derived cytokines. Immunol Rev. 2017;278(1):116–130. doi: 10.1111/imr.12546.

31. Van der Pouw Kraan TC, Van der Zee JS, Boeije LC, et al. The role of IL-13 in IgE synthesis by allergic asthma patients. Clin Exp Immunol. 1998;111(1):129–135. doi: 10.1046/j.1365-2249.1998.00471.x.

32. Naclerio RM. Allergic rhinitis. N Engl J Med. 1991;325(12): 860–869. doi: 10.1056/NEJM199109193251206.

33. Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017;139(6):1723–1734. doi: 10.1016/j.jaci.2017.04.004.

34. Demehri S, Morimoto M, Holtzman MJ, Kopan R. Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma. PLoS Biol. 2009;7(5):e1000067. doi: 10.1371/journal.pbio.1000067.

35. Totte JEE, van der Feltz WT, Hennekam M, et al. Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol. 2016; 175(4):687–695. doi: 10.1111/bjd.14566.

36. Hata TR, Kotol P, Boguniewicz M, et al. History of eczema herpeticum is associated with the inability to induce human betadefensin (HBD)-2, HBD-3 and cathelicidin in the skin of patients with atopic dermatitis. Br J Dermatol. 2010;163(3):659–661. doi: 10.1111/j.1365-2133.2010.09892.x.

37. Cepelak I, Dodig S, Pavic I, et al. Filaggrin and atopic march. Biochem Med. 2019;29(2):020501. doi: 10.11613/BM.2019.020501.

38. Левина Ю.Г., Намазова-Баранова Л.С., Эфендиева К.Е. и др. Применение местных глюкокортикостероидов в лечении дерматитов у детей // Вопросы современной педиатрии. — 2019. — Т. 18. — № 5. — С. 380–385. doi: 10.15690/vsp.v18i5.2063.

39. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: 10.1111/jdv.14891.

40. Намазова-Баранова Л.С., Баранов А.А., Кубанова А.А. и др. Атопический дерматит у детей: современные клинические рекомендации по диагностике и терапии // Вопросы современной педиатрии. — 2016. — Т. 15. — № 3. — С. 279–294. doi: 10.15690/vsp.v15i3.1566.

41. Torrelo A. Methylprednisolone aceponate for atopic dermatitis. Int J Dermatol. 2017;56(6):691–697. doi: 10.1111/ijd.13485.

42. Luger TA. Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 2011;25(3):251–258. doi: 10.1111/j.1468-3083.2010.03789.x.

43. Blume-Peytavi U, Wahn U. Optimizing the treatment of atopic dermatitis in children: a review of the benefit/risk ratio of methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 2011;25(5):508–515. doi: 10.1111/j.1468-3083.2010.03942.x.

44. Ruzicka T. Methylprednisolone aceponate in eczema and other inflammatory skin disorders — a clinical update. Int J Clin Pract. 2006;60(1):85–92. doi: 10.1111/j.1368-5031.2005.00754.x.

45. Zaumseil R, Fuhrmann H, Kecskes A, et al. Methylprednisolone aceponate (Advantan) — an effective topical corticoid therapy with few side effects. In: Macher E, Kolde G, Brocker EB, eds. Jahrbuch der Dermatologie 1992/93. Zulpich, Germany: Blermann Verlag; 1993. S. 247–263.

46. Zentel HJ, Toepert M. Preclinical evaluation of a new topical corticosteroid methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 1994;3(Suppl. 1):S32–S38. doi: 10.1111/j.1468-083.1994.tb01061.x.

47. Haria M, Balfour JA. Methylprednisolone aceponate. A review of its pharmacological properties and therapeutic potential in the topical treatment of eczema. Clin Immunother. 1995;3:241–253. doi: 10.1007/BF03259059.

48. Hoffmann K, Auer T, Stucker M, et al. Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone. J Eur Acad Dermatol Venereol. 1998;10(2):137–142.

49. Nawata H, Okabe T, Yanase T, et al. Mechanism of action and resistance to glucocorticoid and selective glucocorticoid receptor modulator to overcome glucocorticoid-related adverse effects. Clin Exp Allergy Rev. 2008;8(2):53–56. doi: 10.1111/j.1472-9733.2008.00137.x

50. Newton R, Holden NS. Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol Pharmacol. 2007;72(4):799–809. doi: 10.1124/mol.107.038794.

51. Mensing H, Lorenz B. Experience with Methylprednisolone Aceponate (MPA) in patients suffering from acute and chronic eczema — Is Results of a large observational study. Z Hautkr. 1998;73(5):281–285.

52. Niedner N, Zaumseil R-P. Advantan® Milk/Cream/Ointment in Children with Atopic Eczema and other Dermatoses — An Obser vational Study in 558 Children. Aktuelle Derm. 2004;30(6): 200–203. doi: 10.1055/s-2004-814472.

53. Peserico A, Stadtler G, Sebastian M, et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol. 2008;158(4):801–807. doi: 10.1111/j.1365-2133.2008.08436.x.

54. Bieber T, Vick K, Folster-Holst R, et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy. 2007;62(2):184–189. doi: 10.1111/j.1398-9995.2006.01269.x.

55. Ponte LG, Ebert U. Frontiers of rapid itch relief: a review of methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 2012;26(Suppl 6):9–13. doi: 10.1111/j.1468-3083.2012.04711.x.

56. Gong JQ, Lin L, Lin T, et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol. 2006;155(4):680–687. doi: 10.1111/j.1365-2133.2006.07410.x.